Biotron (ASX:BIT) - Managing Director & CEO, Dr Michelle Miller
Managing Director & CEO, Dr Michelle Miller
Sourced: Biotron
Market Herald logo


Be the first with the news that moves the market
  • Biotech company Biotron (BIT) has seen a small climb in its shares after outlining its March quarterly activities
  • In February, the company began testing compounds against SARS-CoV-2 – which is the causative agent of COVID-19
  • So far, Biotron’s compounds have shown positive antiviral activity against a range of coronaviruses
  • The company also focused on its Phase 2 clinical trial for HIV-1
  • Biotron claims its lead drug “unmasks” HIV-infected cells that remain in the body even when using approved treatment drugs
  • A Phase 3 trial is currently in development
  • Additionally, Biotron received over $753,000 under the Australian Federal Government’s R&D Tax Incentive Scheme and remains well funded
  • Biotron is up 13.6 per cent with shares trading for an even 10 cents each

Biotech company Biotron (BIT) has updated the market on its March quarterly activities.


In early February, Biotron announced it would begin testing compounds from its small molecule compound library for antiviral activity against SARS-CoV-2 – which is the root causing agent of the COVID-19 outbreak.

Biotron has compounds within its library that have shown good antiviral activity against a range of coronaviruses. These include human coronaviruses that cause mild, cold-like symptoms, as well as the coronavirus that caused the SARS virus outbreak in 2003.

At this stage, the company is working with groups in Australia and overseas to assess whether its compounds can inhibit growth of the new SARS-CoV-2 coronavirus.

HIV-1 Program

On March 12, Biotron presented more data from its successful BIT225-009 Phase 2 HIV-1 clinical trial at an international conference. The company previously reported that the trial showed that BIT225 caused significant changes to key immune cell populations.

Essentially, Biotron announced at the conference that BIT225 “unmasks” HIV-infected cells that remain in the body despite treatment with approved anti-HIV-1 drugs.

Infected cells are supposedly hidden from the immune system and are why people take lifelong drugs for treatment. Biotron believes that incorporating BIT225 “stimulates the innate immune system so that the body’s cells can see the HIV-infected reservoir cells and take the necessary steps to eliminate any residual virus”.

The announcement of owning a potential future cure for HIV left investors scratching their heads, but nevertheless, saw Biotron’s shares climb healthily.

The company has focused its aims to commercialise its antiviral drugs whilst continuing to progress its clinical HIV-1 program to prepare for more advanced clinical trials, including Phase 3 studies.

Hepatitis B Program

Biotron continues to progress its Hepatitis B virus (HBV) program. Like HIV-1, HBV can be treated with drugs that stop the virus replicating, but these do not get rid of the virus.

Chronic infection with HBV can lead to complications such as cirrhosis and liver cancer, which cause nearly one million deaths worldwide each year.

So far, Biotron’s compounds have showed significant anti-viral activity against HBV, reducing levels of cccDNA (covalently closed circular DNA), as well as other key viral markers. This has led to significant interest from potential partners.

Even though Biotron’s work on its HBV compounds is preclinical, the data further validates its approach to developing antiviral drugs and may provide the company with an early stage development opportunity with a selected partner.


Engaging in these studies this quarter totalled $464,000 and $193,000 of related staff costs. Biotron also spent $128,000 for director fees, salaries and superannuation payments.

Additionally, Biotron received $753,026 under the Australian Federal Government’s R&D Tax Incentive Scheme.

The company is sitting in a solid financial position as it focuses on achieving commercial outcomes for its clinical programs.

Biotron is up 13.6 per cent with shares trading for an even 10 cents each at 11:52 am AEST.

BIT by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.